🇺🇸 FDA
Pipeline program

Live attenuated Japanese encephalitis chimeric virus vaccine

JEC12

Phase 3 mab completed

Quick answer

Live attenuated Japanese encephalitis chimeric virus vaccine for Japanese Encephalitis is a Phase 3 program (mab) at Sanofi Pasteur with 1 ClinicalTrials.gov record(s).

Program details

Company
Sanofi Pasteur
Indication
Japanese Encephalitis
Phase
Phase 3
Modality
mab
Status
completed

Clinical trials